[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Authority, Hong Kong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":200},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,56,83,112,142,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100597448","nurse-led-telehealth-vs-in-person-follow-up-after-total-knee-replacement-100597448",false,"NCT07058623","Nurse-Led Telehealth vs In-Person Follow-Up After Total Knee Replacement","A Randomized Controlled Trial of Nurse-Led Telehealth Versus In-Person Consultations in Detecting Complications and Improving Recovery After Total Knee Replacement","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing their first total knee replacement surgery\n* Within 4 weeks after surgery\n* Medically stable for discharge and suitable for home-based follow-up care\n* Have access to a smartphone and internet (for telehealth participants)\n* Able to communicate effectively in Cantonese\n* Provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Undergoing bilateral or revision total knee replacement surgery\n* Require immediate or intensive medical attention post-surgery (e.g., severe infection, hospitalization over 7 days)\n* Have severe systemic disease (ASA physical status classification III or higher)\n* Lack the technical ability or resources to participate in telehealth consultations\n* Unable to communicate effectively in Cantonese\n* Undergoing surgeries other than first-time total knee replacement","ALL","18 Years",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"NA","Brief Summary\n\nThe goal of this clinical trial is to learn if nurse-led telehealth consultations can help detect complications and support recovery after total knee replacement surgery. The study will compare telehealth nursing consultations to traditional in-person nursing visits.\n\nThe main questions it aims to answer are:\n\n* Can nurse-led telehealth detect post-surgery complications as well as or better than in-person consultations?\n* Does telehealth nursing support better or equivalent recovery outcomes and patient satisfaction compared to in-person care?\n\nParticipants will:\n\n* Be adults who had their first total knee replacement surgery.\n* Receive follow-up care either through telehealth consultations using the HA Go mobile app or through traditional face-to-face nurse visits in the outpatient clinic.\n* Attend scheduled consultations and provide information about their recovery and any complications they experience.\n* Complete surveys about their satisfaction with the care they receive.\n\nThis study will help determine if telehealth nursing consultations can provide safe, effective, and convenient follow-up care for patients after knee replacement surgery, potentially improving access and reducing travel burdens.",[26,27],"Arthroplasty, Replacement, Knee","Osteoarthritis, Knee",[29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Total knee replacement","Knee arthroplasty","Postoperative care","Nurse-led telehealth","Telemedicine nursing consultation","Telehealth follow-up","Orthopedic nursing","Surgical complication detection","Recovery after knee surgery","Patient satisfaction","Outpatient follow-up care","Digital health interventions","HA Go mobile application","Remote patient monitoring","RECRUITING","2025-12-30",{"date":46,"type":47},"2026-01-05","ACTUAL",{"date":49,"type":47},"2025-09-10",{"date":51,"type":20},"2026-06-30",{"name":53,"class":54},"Hospital Authority, Hong Kong","OTHER_GOV",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":55},"100573132","phase-4-faricimab-quarterly-maintenance-for-neovascular-age-related-macular-degeneration-100573132","NCT06742307","Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration","Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series","Fixed farcimab","Inclusion Criteria:\n\nSubjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3.\n\nExclusion Criteria:\n\n* eyes that received any anti-VEGF therapy in the prior six months,\n* eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation),\n* concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period.","50 Years",{"count":66,"type":20},40,[68],"PHASE4","We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.",[71],"Macular Degeneration Choroidal Neovascularization",[73,74],"neovascular age related macular degeneration","faricimab","2025-09-26",{"date":77,"type":47},"2025-10-01",{"date":79,"type":47},"2025-08-21",{"date":81,"type":20},"2027-02-01",{"name":53,"class":54},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":55},"100593402","effects-of-mobile-based-mindfulness-intervention-to-reduce-preoperative-anxiety-for-patients-undergoing-elective-surgery-100593402","NCT07005973","Effects of Mobile-based Mindfulness Intervention to Reduce Preoperative Anxiety for Patients Undergoing Elective Surgery","Effects of Mobile-based Mindfulness Intervention to Reduce Preoperative Anxiety for Patients Undergoing Elective Surgery: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* adult (age\\>= 18 years old)\n* scheduled to undergo non-emergency surgery under general anesthesia (GA)\n* use of smart phone\n* able to understand the Chinese language and express their feelings sufficiently\n* STAI-T score \\>=40\n\nExclusion Criteria:\n\n* unable to provide informed consent\n* history or current treatment for psychological complaints\n* serious physical or psychological co-morbidities\n* hearing or vision impairment\n* patients withdrawal from continuing to participate in the study",true,{"count":66,"type":20},[23],"This study is a pilot randomized controlled trial (RCT) conducted at Tin Shui Wai Hospital to evaluate the effectiveness of a mobile-based mindfulness intervention in reducing preoperative anxiety among patients scheduled for elective surgery.\n\nAim: To determine if a 4-week mindfulness program delivered via a mobile app can reduce preoperative anxiety, compared to standard care.\n\nDesign:\n\nParallel-arm RCT with 40 participants (20 in each group). Participants are randomly assigned to either the intervention group (mobile-based mindfulness intervention + usual care) or control group (usual care only).\n\nThe intervention uses a free and anonymous mindfulness mobile app developed by The University of Hong Kong.\n\nPrimary Outcome:\n\nPreoperative anxiety level on the day of surgery, will be assessed using the STAI-S questionnaire.\n\nSecondary Outcomes:\n\nPostoperative pain levels, use of analgesics, emergency department revisit rate, and user satisfaction with the app.\n\nData Collection:\n\nAnxiety levels are measured at baseline and before surgery. Pain levels and analgesic use are recorded postoperatively. Emergency visits and usability feedback are collected post-discharge.\n\nSignificance:\n\nThe study addresses a gap in evidence for mobile mindfulness interventions in Chinese surgical patients.\n\nFindings may support the integration of low-cost, app-based mindfulness into preoperative care.",[95,96,97,98],"Mobile-based Mindfulness Intervention to Reduce Preoperative Anxiety","Pre-operative Anxiety","Postoperative Pain","Postoperative Use of Analgesics",[100,101,102,103],"Mobile-based mindfulness","pre-operative anxiety","post-operative pain","postoperative use of analgesics","2025-09-09",{"date":106,"type":47},"2025-09-11",{"date":108,"type":47},"2025-06-13",{"date":110,"type":20},"2026-12-31",{"name":53,"class":54},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100552496","efficacy-of-sglt2-inhibitors-in-adults-with-sepsis-100552496","NCT06473844","Efficacy of SGLT2 Inhibitors in Adults With Sepsis","Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or above\n* New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)\n* Provision of signed and dated informed consent form from participant or surrogate\n* Ability to take and adhere to oral and enteral medication regimen\n* Willingness to comply\n\nExclusion Criteria:\n\n* Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)\n* Impaired renal function\n* Clinically unstable or in refractory hypotension\n* History of ketoacidosis\n* Gastrointestinal surgery or GI absorption \u002F malabsorption disorder\n* Pregnancy\n* Known allergic or hypersensitivity reactions to any SGLT2 inhibitors\n* Treatment with another investigational drug or other interventions within 30 days prior to trial",{"count":120,"type":20},60,[23],"Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:\n\n(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.\n\n(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.",[124,125,126,127,128],"Sepsis","Inflammation","SGLT2 Inhibitors","Critically Ill","Organ Dysfunction Syndrome",[130,124,131,127,132],"SGLT2 inhibitors","Inflammatory Markers","Organ dysfunction","2025-03-17",{"date":135,"type":47},"2025-03-19",{"date":137,"type":47},"2025-03-05",{"date":139,"type":20},"2027-02-28",{"name":53,"class":54},3,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":55},"100571343","phase-2-topical-ruxolitinib-for-face-and-neck-vitiligo-of-adult-chinese-patients-refractory-to-topical-tacrolimus-100571343","NCT06719024","Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus","A Randomized Controlled Trial to Assess the Efficacy and Safety of Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus","RCT","Inclusion Criteria:\n\n* 18 - 85 year old\n* Have a clinical diagnosis of stable non-segmental vitiligo\n* Depigmentation including at least 0.5% of the BSA on the face and neck\n* Previously treated with topical tacrolimus 0.1% BD for at least 3 months without significant response\n* Agree to stop using any topical treatments on face and neck and systemic treatment for vitiligo during the washout period until the trial concludes. Use of over-the-counter products approved by the investigator and camouflage makeup is allowed\n* Both male and female patients must commit to using effective birth control to prevent pregnancy or fathering a child throughout the study\n* Subjects or their legally authorized representative, if applicable, must be able to understand and willing to provide informed consent at Screening visit\n\nExclusion Criteria:\n\n* Patients who refuse to give consent\n* Presence of different vitiligo types or other skin depigmentation conditions like piebaldism or leprosy, etc.\n* History of using depigmentation treatments other than hydroquinone for vitiligo or pigmentation issues\n* Any skin condition affecting study participation, active skin infections one week before the study starts, issues impacting vitiligo evaluation, or serious health problems limiting involvement or increasing risk\n* Significant medical disease that may hinder use of topical JAK inhibitor, e.g. serious infection, untreated chronic hepatitis, malignancy within 5 years except adequately treated non metastatic cancer, evidence of clinically significant or uncontrolled cardiovascular disease, thrombosis including DVT and PE, blood abnormality including significant thrombocytopenia, anaemia (Hb \\\u003C10g\u002FdL) and significant neutropenia, substance misuse\n* Specific treatment use within certain periods before starting (Baseline visit):\n\n  1 week for topical vitiligo treatments 4 weeks for immunomodulators, photosensitizers, oral retinoids, methoxsalen, or live vaccines 8 weeks for laser or phototherapy on face and neck 12 weeks for biologics\n* Any prior application of topical or oral JAK inhibitors\n* Hemoglobin under 10 g\u002FdL, significant liver dysfunction, and\u002For evidence of HIV infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency\n* Females of childbearing potential who are pregnant, during breastfeeding period, or those planning pregnancy during the study\n* Those unlikely or unable to comply with the requirements of this study protocol","85 Years",{"count":152,"type":20},20,[154,155],"PHASE2","PHASE3","This trial is a prospective, open-label, single-center, split face randomized controlled study comparing 1.5% topical Ruxolitinib cream twice daily (BD) to aqueous cream in treating non-segmental vitiligo (NSV) of the face and neck in patient previous failed to respond to topical tacrolimus 0.1%. Aqueous cream twice daily application will be used as control group treatment. Patients with stable NSV at least 0.5% of their total body surface area (BSA) on the face and neck, as determined by the fingertip method, are screened. Recruited subjects will be asked to review their impression of change of their lesion by the end of the study using a 7-point scale.",[158],"Vitiligo",[160,161,162],"non-segmental vitiligo","randomized controlled trial","Chinese","2024-12-02",{"date":165,"type":47},"2024-12-05",{"date":167,"type":47},"2024-11-29",{"date":169,"type":20},"2026-01-30",{"name":53,"class":54},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":178,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":55},"100559063","tdcs-as-augmentation-therapy-to-cognitive-training-in-mild-dementia-100559063","NCT06559254","TDCS as Augmentation Therapy to Cognitive Training in Mild Dementia","Randomized Controlled Trial of Transcranial Direct Current Stimulation (tDCS) as Augmentation Therapy to Cognitive Training (CT) in Individuals With Major Neurocognitive Disorder (MND) of Mild Severity","Inclusion Criteria:\n\n* 65 years of age or above\n* Right-handedness Chinese as defined by Edinburgh handedness inventory\n* Cantonese speaking\n* Fulfil the criteria of Major neurocognitive disorder, as defined by the 5 th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM- 5)\n* Clinical Dementia Rating Global score = 1\n\nExclusion Criteria:\n\n* Active diagnosis of mood disorder or psychosis\n* Alcohol or substance dependence\n* Initiation or change in dose of cognitive enhancer within 6 months prior to the onset of the study 14\n* Poor physical condition and mobility\n* Having regular cognitive training (as defined by at least three 1-hour weekly structured and standardized cognitive training in recent 3 months) 15\n* Receiving tDCS within 2 months prior to the onset of study 16\n* Significant communication or visual impairment\n* Having metal implant in area above upper back, or having metal crown or metal brace, or pacemaker","65 Years",{"count":180,"type":20},36,[23],"Due to increase in life expectancy, major neurocognitive disorder (MND) becoming increasingly important as reflected in the increasing number in dementia population, as well as in burden to health care system and to caregiver.\n\nAmong current treatment, cognitive training has shown to have significant outcome in cognitive impaired patient. But the effect is reported to be small and might not be long-lasting. In consideration of the neuronal excitability effect in tDCS, it may consolidate the effect of cognitive training if used simultaneously. The study will investigate on efficacy of tDCS as combined intervention to cognitive training.\n\nThe study aims to investigate the efficacy of 2-week (5 sessions per week) tDCS to augment cognitive training in subjects with MND with clinically mild severity. Patients with diagnosis of MND or dementia from HKWC will be recruited with inclusion and exclusion criteria listed. The eligible participants will be randomized to receive either active intervention (active tDCS) or sham (sham tDCS) as control with cognitive training simultaneously.\n\nEach session lasts for 20 minutes. The subjects will be allocated to either interventional or control group using block randomization. Block of 4 will be used to allocate subjects at 1:1 ratio between two groups. Both the participants and investigators responsible for assessment and data analysis will be blinded to the group allocation. Primary and secondary outcome will be assessed at baseline, week 2 (after course of intervention) and 4 weeks after the course of intervention. Baseline assessment assesses on demographic data (e.g. age, gender, years of education), clinical data with full psychiatric assessment and access to previous medical record, neuropsychiatric data (HK-MoCA and CNPI). Primary outcomes includes N-back (cognitive training) performance, forward and backward digit span. Secondary outcomes includes measurement on dementia rating and trail making test. In data analysis, any group differences in demographics and clinical profiles between the intervention and sham group at baseline will be assess. ANOVA will be performed to examine the effect of time and intervention on primary outcome and other cognitive assessment across time points. Potential confounders will be adjusted.\n\nBaseline assessments and outcome measures is either psychiatric assessment, clinician rating scales or cognitive assessment performed with investigator.",[184],"Major Neurocognitive Disorder",[186,187,188,189,190],"mild dementia","major neurocognitive disorder","tdcs","transcranial direct current stimulation","cognitive training","NOT_YET_RECRUITING","2024-08-14",{"date":194,"type":47},"2024-08-19",{"date":196,"type":20},"2024-09-01",{"date":198,"type":20},"2025-09-30",{"name":53,"class":54},""]